1-3 of 3
Keywords: Denosumab
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Predictive Power of Bone Turnover Biomarkers to Estimate Bone Mineral Density after Kidney Transplantation with or without Denosumab: A post hoc Analysis of the POSTOP Study

Open Access
Subject Area:
Cardiovascular System , Nephrology
Nadine Heimgartner, Nicole Graf, Diana Frey, Lanja Saleh, Rudolf P. Wüthrich, Marco Bonani
Journal: Kidney and Blood Pressure Research
Kidney Blood Press Res (2020) 45 (5): 758–767.
https://doi.org/10.1159/000510565
Published Online: 30 September 2020
..., respectively. Half of the collective was treated with denosumab twice yearly in addition to the standard treatment with calcium and vitamin D. Results: Changes in bone formation markers BSAP and P1NP within 3 months showed a significant negative correlation to changes in BMD at the hip within 6 months...
View article titled, Predictive Power of Bone Turnover Biomarkers to Estimate Bone Mineral Density after Kidney Transplantation with or without Denosumab: A post hoc Analysis of the POSTOP Study
Open the PDF for Predictive Power of Bone Turnover Biomarkers to Estimate Bone Mineral Density after Kidney Transplantation with or without Denosumab: A post hoc Analysis of the POSTOP Study in another window
Journal Articles

Follow-Up of Bone Mineral Density Changes in de novo Kidney Transplant Recipients Treated with Two Doses of the Receptor Activator of Nuclear Factor κB Ligand Inhibitor Denosumab

Open Access
Subject Area:
Cardiovascular System , Nephrology
Claudia Kobel, Diana Frey, Nicole Graf, Rudolf P. Wüthrich, Marco Bonani
Journal: Kidney and Blood Pressure Research
Kidney Blood Press Res (2019) 44 (5): 1285–1293.
https://doi.org/10.1159/000503066
Published Online: 15 October 2019
...Claudia Kobel; Diana Frey; Nicole Graf; Rudolf P. Wüthrich; Marco Bonani Background: Studies in women with post-menopausal osteoporosis have shown that discontinuation of treatment with denosumab leads to an increased risk of vertebral fractures because of rebound bone turnover and rapid loss...
View article titled, Follow-Up of Bone Mineral Density Changes in de novo Kidney Transplant Recipients Treated with Two Doses of the Receptor Activator of Nuclear Factor κB Ligand Inhibitor Denosumab
Open the PDF for Follow-Up of Bone Mineral Density Changes in de novo Kidney Transplant Recipients Treated with Two Doses of the Receptor Activator of Nuclear Factor κB Ligand Inhibitor Denosumab in another window
Journal Articles

Effect of Denosumab on Peripheral Compartmental Bone Density, Microarchitecture and Estimated Bone Strength in De Novo Kidney Transplant Recipients

Open Access
Subject Area:
Cardiovascular System , Nephrology
Marco Bonani, Ursina Meyer, Diana Frey, Nicole Graf, Heike A. Bischoff-Ferrari, Rudolf P. Wüthrich
Journal: Kidney and Blood Pressure Research
Kidney Blood Press Res (2016) 41 (5): 614–622.
https://doi.org/10.1159/000447930
Published Online: 14 September 2016
...Marco Bonani; Ursina Meyer; Diana Frey; Nicole Graf; Heike A. Bischoff-Ferrari; Rudolf P. Wüthrich Background/Aims: In a randomized controlled clinical trial in kidney transplant recipients (NCT01377467) we have recently shown that RANKL inhibition with denosumab significantly improved areal bone...
View article titled, Effect of Denosumab on Peripheral Compartmental Bone Density, Microarchitecture and Estimated Bone Strength in De Novo Kidney Transplant Recipients
Open the PDF for Effect of Denosumab on Peripheral Compartmental Bone Density, Microarchitecture and Estimated Bone Strength in De Novo Kidney Transplant Recipients in another window